All In Biotech

Drug Trial Radar · NCT03020030

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

560

Actual

Start

Mar 3, 2017

Primary completion

Nov 30, 2026

Study completion Nov 2034

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Servier
First posted
Jan 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells. ALL is always fatal if it is not treated. With current treatments, most children and adolescents with this disease will be cured. The standard treatment for ALL involves about 2 years of chemotherapy. The drugs that are used, and the doses of the drugs, are similar but not identical for all children and adolescents with ALL. Some children and adolescents receive stronger treatment, especially during the first several months. A number of factors are used to decide how strong the treatment should be to give the best chance for cure. These factors are called "risk factors". This trial is studying the use of a new, updated set of risk factors to decide how strong the treatment will be. The study also will test a new way of dosing a chemotherapy drug called pegaspargase (which is part of the standard treatment for ALL) based on checking levels of the drug in the blood and adjusting the dose based on the levels.

Conditions

  • Acute Lymphoblastic Leukemia, Pediatric

Interventions

  • PegaspargaseDrug

    Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization

  • Erwinia asparaginaseDrug

    Only for patients with Pegaspargase allergy or silent inactivation.

  • CyclophosphamideDrug

    Standard of Care

  • CYTARABINEDrug

    Standard of Care

  • DASATINIBDrug

    Standard of Care

  • DEXAMETHASONEDrug

    Standard of Care

  • DexrazoxaneDrug

    Standard of Care

  • DoxorubicinDrug

    Standard of Care

  • ETOPOSIDEDrug

    Standard of Care

  • HYDROCORTISONEDrug

    Standard of Care

  • LEUCOVORIN CALCIUMDrug

    Standard of Care

  • MERCAPTOPURINEDrug

    Standard of Care

  • METHOTREXATEDrug

    Standard of Care

  • NELARABINEDrug

    Standard of Care

  • VincristineDrug

    Standard of Care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Remission RateTime frame: After 1 month of treatment (Induction IA) for all participants, assessed at the end of first month of treatment in all participants through study completion (expected to take 4-5 years to accrue)
  2. Event-Free SurvivalTime frame: From registration to the time of induction failure, relapse, death, or second malignancy, whichever came first, assessed up to 60 months.

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Hasbro Children's Hospital / Rhode Island Hospital

    Providence, Rhode Island

  • Hospital Sainte Justine, University of Montreal

    Montreal, Quebec, Canada

  • Centre Hospitalier U. de Quebec

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.